MUSE Microscopy Appoints PathGroup Founder and Co-Chairman Dr. Ben W. Davis to Board of Directors

Rapid. Slide-Free. Tissue-to-Digital Pathology.

SmartPath UV Fluorescence

SmartPath Instrument

Pathology pioneer brings four decades of clinical, operating, and governance experience to MUSE as the Company advances its tissue-to-digital imaging platform.

IRVINE, CA, UNITED STATES, September 14, 2026 /EINPresswire.com/ — MUSE Microscopy™, Inc., a pioneer in slide-free, tissue-to-digital pathology, today announced the appointment of Ben W. Davis, M.D., founder of PathGroup and current member of the PathGroup Board of Directors, to the MUSE Board of Directors. Dr. Davis brings extensive clinical, entrepreneurial, and national laboratory leadership experience as MUSE advances the development and commercialization of its SmartPath MUSE Technology™ (SmartPath) platform.

Dr. Davis founded PathGroup in 1996 and served as its longtime Chief Executive Officer, helping build the organization into a national provider of anatomic, clinical, molecular, and digital pathology services. PathGroup now serves more than 250 hospitals and health systems, as well as thousands of physician groups and surgery centers. His experience scaling a physician-led diagnostics organization is directly aligned with MUSE’s opportunity to introduce a new tissue-imaging workflow to pathologists, laboratories, and health systems.

“Dr. Davis is one of the few leaders in American pathology who has seen the diagnostic enterprise from every vantage point—as a physician, laboratory operator, founder, chief executive, and board leader. He understands what pathologists need, what health systems require before adopting new technology, and what it takes to build the infrastructure and commercial discipline necessary to scale. As MUSE moves from technical achievement into clinical validation and broader market execution, his perspective will be invaluable.” — Matthew Nuñez, Chief Executive Officer, MUSE Microscopy

As a director, Dr. Davis will advise MUSE on corporate governance, clinical and laboratory workflow integration, commercialization, health-system adoption, strategic partnerships, and responsible operating scale. His participation will help ensure that MUSE’s strategy remains grounded in the practical needs of pathologists and laboratory leaders.

“Breakthrough technology creates opportunity, but disciplined governance and operating judgment determine whether that opportunity becomes an enduring company. Ben has spent decades translating scientific progress into trusted diagnostic services at scale. His experience will sharpen our priorities, strengthen our governance, and help MUSE move into its next phase with purpose and discipline.” — Gary Fudge, Chairman of the Board, MUSE Microscopy

About MUSE Microscopy, Inc.

MUSE Microscopy specializes in the application of Microscopy with Ultraviolet Surface Excitation (MUSE). We have developed a MUSE-enabled imaging system for diagnostic assistance in pathology and research applications. Our commercial product, SmartPath MUSE Technology™ (SmartPath)*, is a slide-free, direct-to-digital imaging platform that aims to transform the patient experience and provide healthcare professionals with rapid diagnostic information through digital imaging.

*SmartPath MUSE Technology is under development and pending U.S. Food and Drug Administration clearance or approval. It is not currently cleared or approved for clinical diagnostic use in the United States.

Forward-Looking Statements

Forward-looking statements in this press release are based on our future expectations, plans, prospects, and assumptions regarding matters that are not historical facts, and may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “termed,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance.

Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law.

MEDIA CONTACT:

Matthew Nuñez

Tel: 949.813.6121

[email protected]

www.musemicroscopy.com

Matthew Nuñez
MUSE Microscopy
+1 949-813-6121
[email protected]
Visit us on social media:
LinkedIn
Instagram
Facebook
X

SmartPath by MUSE Microscopy – Slide-Free Starts Here